Accueil   Diary - News   All news Alizé Pharma will present clinical results

Alizé Pharma will present clinical results

Alizé Pharma presents clinical results from the AZP-531 program at the American Diabetes Association 75th Scientific Sessions

Final data will be revealed from Phase Ia trial in healthy volunteers and Phase Ib trial in overweight/obese subjects

 

Alizé Pharma SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, will present the results from two Phase I clinical trials with its unacylated ghrelin analog AZP-531 during the 75th Scientific Sessions of the American Diabetes Association (ADA) in Boston on June 5-9,2015.

 

 Read the press release

 

ALIZE  NEWSLETTER

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree